Emmaus Life Sciences, Inc.
corporate_fare Company Profile
Emmaus Life Sciences, Inc. (OTC:EMMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for EMMA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for EMMA spans 8-K, 10-Q, 4, 10-K.
Recent high-impact activity:
- Emmaus Q3 Revenue Falls to $1.9M, Net Loss Widens to $4.7M
- Emmaus Q3 10-Q: Going Concern Reaffirmed, Cash Down to $971K, $1.1M New Secured Debt
- CEO Willis Lee Buys $18K of Emmaus Stock Across Six Trades
- Emmaus Q2 Revenue Jumps 124% on NeoImmuneTech License Deal
- Emmaus Life Sciences Q2 2026: Net Income Reaches $1.3M as Revenue Jumps 124%
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 9,890 shares in EMMA as of the October 30, 2026 settlement, a 229.2% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 5.6% of EMMA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.